104 related articles for article (PubMed ID: 23801559)
1. Reopening the case for anti-basal ganglia antibodies (ABGAs): identification of dopamine-2 receptor antibodies associated with movement disorders.
Balint B; Bhatia K
Mov Disord; 2013 Jun; 28(6):733. PubMed ID: 23801559
[No Abstract] [Full Text] [Related]
2. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders.
Dale RC; Merheb V; Pillai S; Wang D; Cantrill L; Murphy TK; Ben-Pazi H; Varadkar S; Aumann TD; Horne MK; Church AJ; Fath T; Brilot F
Brain; 2012 Nov; 135(Pt 11):3453-68. PubMed ID: 23065479
[TBL] [Abstract][Full Text] [Related]
3. More movements in neuroimmunology.
Lim M; Vincent A
Brain; 2012 Nov; 135(Pt 11):3201-2. PubMed ID: 23169915
[No Abstract] [Full Text] [Related]
4. Antibody mediated encephalitis.
Ingram G; Robertson NP
J Neurol; 2013 Apr; 260(4):1187-90. PubMed ID: 23515700
[No Abstract] [Full Text] [Related]
5. [Autoantibodies Associated with Autoimmune Basal Ganglia Disorders].
Sakuma H
Brain Nerve; 2018 Apr; 70(4):363-369. PubMed ID: 29632284
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor.
Mohammad SS; Sinclair K; Pillai S; Merheb V; Aumann TD; Gill D; Dale RC; Brilot F
Mov Disord; 2014 Jan; 29(1):117-22. PubMed ID: 24115338
[TBL] [Abstract][Full Text] [Related]
7. [Anti-basal ganglia antibody].
Hayashi M
Brain Nerve; 2013 Apr; 65(4):377-84. PubMed ID: 23568985
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders.
Sinmaz N; Tea F; Pilli D; Zou A; Amatoury M; Nguyen T; Merheb V; Ramanathan S; Cooper ST; Dale RC; Brilot F
Acta Neuropathol Commun; 2016 Dec; 4(1):126. PubMed ID: 27908295
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry.
Sinmaz N; Amatoury M; Merheb V; Ramanathan S; Dale RC; Brilot F
Ann N Y Acad Sci; 2015 Sep; 1351():22-38. PubMed ID: 26083906
[TBL] [Abstract][Full Text] [Related]
10. Reversible dementia and insomnia in ABGA related encephalitis.
Mumoli L; Magro G; Le Piane E; Bosco D
Sleep Med; 2024 Jun; 118():29-31. PubMed ID: 38581805
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders.
Tanaka S; Matsunaga H; Kimura M; Tatsumi Ki; Hidaka Y; Takano T; Uema T; Takeda M; Amino N
J Neuroimmunol; 2003 Aug; 141(1-2):155-64. PubMed ID: 12965267
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children.
Pathmanandavel K; Starling J; Merheb V; Ramanathan S; Sinmaz N; Dale RC; Brilot F
Biol Psychiatry; 2015 Mar; 77(6):537-47. PubMed ID: 25168608
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome.
Tanaka S; Kuratsune H; Hidaka Y; Hakariya Y; Tatsumi KI; Takano T; Kanakura Y; Amino N
Int J Mol Med; 2003 Aug; 12(2):225-30. PubMed ID: 12851722
[TBL] [Abstract][Full Text] [Related]
14. Anti-dopamine D2 receptor antibodies in chronic tic disorders.
Addabbo F; Baglioni V; Schrag A; Schwarz MJ; Dietrich A; Hoekstra PJ; Martino D; Buttiglione M;
Dev Med Child Neurol; 2020 Oct; 62(10):1205-1212. PubMed ID: 32644201
[TBL] [Abstract][Full Text] [Related]
15. Child Neurology: Treatable bilateral striatal lesions related to anti-dopamine 2 receptor autoimmunity.
Marques-Matos C; Melo C; Sampaio M; Rodrigues E; Sousa R; Alves D
Neurology; 2018 Jul; 91(2):98-101. PubMed ID: 29987177
[No Abstract] [Full Text] [Related]
16. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease.
Cazorla M; Kang UJ; Kellendonk C
Mov Disord; 2015 Jun; 30(7):895-903. PubMed ID: 26018615
[TBL] [Abstract][Full Text] [Related]
17. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class.
Castillo-Gómez E; Oliveira B; Tapken D; Bertrand S; Klein-Schmidt C; Pan H; Zafeiriou P; Steiner J; Jurek B; Trippe R; Prüss H; Zimmermann WH; Bertrand D; Ehrenreich H; Hollmann M
Mol Psychiatry; 2017 Dec; 22(12):1776-1784. PubMed ID: 27502473
[TBL] [Abstract][Full Text] [Related]
18. Reply to: N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness.
Kayser MS; Dalmau J
Biol Psychiatry; 2016 May; 79(9):e63. PubMed ID: 26187407
[No Abstract] [Full Text] [Related]
19. The pharmacology of tardive dyskinesias.
Klawans HL
Am J Psychiatry; 1973 Jan; 130(1):82-6. PubMed ID: 4264755
[No Abstract] [Full Text] [Related]
20. Fact or fiction? Examining a role for N-methyl-D-aspartate receptor autoantibodies in psychiatric illness.
Kayser MS
Biol Psychiatry; 2015 Mar; 77(6):506-7. PubMed ID: 25687429
[No Abstract] [Full Text] [Related]
[Next] [New Search]
